Proud to sponsor:
April 17-22 | Virtual
Digital Biomarker Discovery Platform
Biomarker Discovery Platform of data modeling that can be
adapted cross-disorder and readied for rapid scaling.
nQ Medical’s artificial intelligence-powered computational biomarker yields powerful insights. We believe that the way our fingers interact with smart phones and computers can reveal the presence of certain neuromotor and neurocognition diseases like Parkinson’s, Alzheimer’s, ALS, and Multiple Sclerosis.
Decentralized Clinical Trials
The potential of our technology has been shown in clinical research at MIT, backed by the Michael J. Fox Foundation, the Cleveland Clinic and Massachusetts General Hospital.
Remote Patient Monitoring/Ambient Telemetry
The fine control of typing and touch screen kinematics, as well as the frequent use of personal devices like smart phones brings real world data to patients, caregivers, and clinicians.
Challenge Met By Machine Learning
nQ uses machine learning to evaluate information obtained from the daily use of mechanical and touchscreen devices. Six clinical studies have demonstrated our ability to detect the pathological signs of neurological disease sooner than the tools we have today.
Beyond the potential for early detection of symptoms, our AI technology supports clinical trials by improving accuracy and efficiency in recruitment, 24/7, passive monitoring of disease progression from home, and measuring the impact of therapy on outcomes at a far more granular level than current gold standards.
What’s more, our platform provides unified data management across the entire lifecycle, from clinical trials to clinician dashboards, and from patient engagement to population health.
Key Uses of nQ’s Patented AI Technology
Recruitment and Support for
nQ addresses the real challenges faced by clinical trials head on. Specifically, it helps with:
- Remote, online recruitment of study participants by improving patient targeting and screening, thereby shrinking recruitment time.
- Dependence on in-clinic observation is reduced by relying on at-home, unbiased real-world data.
- Offers the potential to shape clinical trial design for neurodegenerative diseases with the earliest measure of therapeutic impact, thanks to passive, continuous monitoring of patients.
Exploratory Development of Future Applications to Measure Disease Progression
Clinical applications in development include:
- A mobile platform used to monitor patient care remotely under the guidance of a healthcare professional in conjunction with other prescribed therapy.
- A digital medicine device that supports clinical drug titration decisions, and a tool for patient engagement and adherence as well as caregiver observation.
What Specialists Think
In a recent survey† of 2,305 movement disorder specialists, 95% of respondents indicated that the ability to monitor patients remotely is extremely valuable, very valuable or valuable.
Of current methods for the detection and monitoring of Parkinson’s Disease that are most in need of improvement, they single out:
- The specificity and sensitivity of collected data for critical decision making (76%)
- The lack of access to real-world, at home, patient data (56%)
- The subjective nature of data collecting (55%)
Furthermore, specialists feel that the availability of remote monitoring and disease progression data, like nQ provides, could potentially positively impact patient care by:
- Helping more accurately titrate medication (72%)
- Providing useful data to support treatment decisions (71%)
- Encouraging patients to become more involved in therapy (63%)
- Improving patient adherence to medication (53%)
- Assisting patients and caregivers better understand and manage the disease (50%)
† Areas of improvement in tools currently available for early detection and disease monitoring of Parkinson’s. US Movement Disorder Specialist Survey. SERMO. February 19, 2019.
Our Clinical Partners
nQ Medical in the News
nQ Medical from the AAN21 conference
In this interview, Teresa tells Paul about the science behind the technology and how it could reshape the future of cognitive screening. She also discusses her views on AI, machine learning and digitalisation of healthcare, particularly in the wake of COVID and shares...
nQ won the #VirtualSouthSummit Health & Wellbeing contest on Feb 22. See the announcement: Here
nQ featured in another International Clinical Trials article discussing the digital race for early detection and cure for neurodegenerative disease. Read here
Pharmaphorum does a deep dive with nQ Medical to discuss Digital Health:...
“Arroyo-Gallego is an exceptional candidate, who is doing an extremely pioneering job and deserves recognition.” …”(although) she is at the beginning of her career, she will be one of the leading players in this industry for many years to come.”...
At the end of 2019, EyeforPharma awarded nQ Medical the Most Valuable Breakthrough/Discovery award in Philadelphia. https://www.eyeforpharma.com/awards-evening/
nQ Medical Ranked #4 from 3,500 applicants from Pepperdine Graziadio Business School List of Most Fundable Companies® for 2019 Read More
nQ Medical is please to be recognized by a distinguished selection panel of CEOs,CIOs, VCs, Industry Analysts, and PharmaTech Outlook’s Editorial Board as one of the Top 10 eClinical Trial solution providers in 2019.
Our Leadership Team
R. A. Bavasso
Founder & Executive Chairman
Teresa Arroyo Gallego, PhD
Ijah Mondesire-Crump, MD
VP Regulatory & Quality
Rahul Mahajan , MD
Our Board of Advisors
John Baldoni, PhD
SVP, R&D, GSK
Naomi Fried, PhD
David Kreutter, PhD
Maulik Majmudar, MD
Chief Medical Officer, Health & Wellness, Amazon
Zoltan Mari, MD
Chief Medical Officer at Walgreens
David Lee Scher, MD
Peer Reviewed Clinical Publications
Movement Disorders, 2019
Journal of Medical Internet Research, 2018
IEEE Transactions on Biomedical Engineering, 2017
Scientific Reports, 2016
Scientific Reports, 2015
Get In Touch
Want to learn more about nQ Medical? Drop us a note and let us show you how we can help.
245 Main Street
NQ Medical’s Software has been designated Breakthrough Status but is is not yet cleared by FDA. Any depictions of the technology are intended to be conceptual and illustrative and are not intended to convey exact representations of anatomy, physiology, structure, positioning, or performance of the technology.